Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Main catalyst coming soon: FDA approval of NDE for Ovaprene, non hormonal birth control product. The company already in partnership with Bayer and NIH on this.
$1B
market. NDE approval will trigger the start of a pivotal Ph3 trial this year. Hopefully, their second FDA-approved product by next year. The trial will only cost them $5, and they get a bonus check from Bayer
$20M
on start.
Other pipeline catalysts soon:
1)Xaciato marketing/sales/revenue by Q4 or earlier.
2) VVA-1 Ph2 data: Q3
3) Sildenafil Ph2 data: Q3
From Someone Very Smart
Path to 4.5B MC.
+Initial 10m payment from Organon for Xaciato commencements.
+Sales growth from XACIATO creating a close to breakeven or better cash flow within 2 years. Share price is a reflection of expected future value. Strong sales = big upside potential.
+ Ovaprene IDE acceptance. Bayer thinks that Ovaprene could be it's next billion dollar BC option.
+ $20m Ovaprene payment from Bayer. Would show confidence, solidify balance sheet and give investors more confidence.
+Eventual Ovaprene Approval. $300m+ in incentives + double digit royalties.
+ Sildenafil. Highly likely to be a billion+ annual sales drug with no competition if approved. It alone could boost us to a multi-billion dollar market cap.
+ LARC
+ Deeper pipeline
3 - 5 year horizon. Pretty straightforward path to multi-billion territory."
Long shots - Sale of any of the top 4 candidates. BO of company outright. $6-10 overnight.
Steady and sure... up DARE goes...
Roth capital has a 17$ price target up from 11$, im saying 3$ is very conservative
Yes I am... get ready!
Nice, steady movement upward.
What does Monday have in store?
The spring is coiled and ready to release a whole lot of energy.
Jayzus and Baby Jayzus, you still in this?
They tried to keep it down this morning but failed.
UP from here!
NOOOOOOOOOOOOOOOOOOOOOOOOOOOO
If shares were still issued as certificates, this would be tucked away in the sock drawer.
MAYBEEEEEEEEEEEEEE TODAYYYYYYYYYYYYYYY?????
I am going to initiate a subscription service based on my personal picks.
Whatever I recommend, do the opposite.
You will ALWAYS be a winner!!
52 week lows coming
It appears 1.36 was bottom.
We shall see...
Might be a good bottom, back watching, GLTY
Roth Capital just raised the PT from $11 to $17
SP is spiking
ORGANON!
It should be an interesting day!
Some playing for pennies will get burned soon.
Pretty coiled up here
Biotechs appear to be the safe haven in this situation.
Loading up in a biotech with a strong pipeline and pending partnership is a no brainer.
Welcome new investors!
Bucking the trend.
Many see the opportunity here...
Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Daré Bioscience to Participate in Upcoming Conferences
https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-participate-upcoming-conferences
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences:
2022 BIO CEO & Investor Conference
February 14-17, 2022, New York Marriott Marquis and Virtual
In-person Presentation Monday, February 14, 2022 at 2:15 p.m. EST
SVB Leerink Virtual 11th Annual Global Healthcare Conference
February 14-18, 2022, Virtual
Presentation Thursday, February 17, 2022 at 1:00 p.m. EST
Webcast link: https://wsw.com/webcast/svbleerink67/dare/2615800
An archived webcast of Ms. Johnson’s presentation at the SVB Leerink Virtual 11th Annual Global Healthcare Conference will be available until March 3, 2022 under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATOTM (clindamycin phosphate), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s product portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATOTM, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake.robison@canalecomm.com
619.849.5383
Source: Daré Bioscience, Inc.
Lol, no not me, but Damn!
Did you just gulp up a half-mil?
ASK taken out up to 1.52 one hour ago
I was outside and missed all the action.
and there we go... 1.38 arghhhhhhhhhhhhhhhh
I hope everyone got their fill.
It should be only up from here.
I sincerely thought the bottom was in @1.59
Then, Biden, Putin, and the FED proved me wrong.
We shall see, but under 1.40 is a stretch...
heck
what do I know!
Almost pulled trigger @$1.51 yesterday, Markets are wack right now, Still watching closely, thx again
We opened up a dock for a limited time only.
Take advantage while you can.
Looks like an interesting load zone
Hi folks, we entered. Not going to say to much other than have some patience with this. Could be an easy double here. GL $$$$$
Maxim Group, this morning, raised their PT to $4 from $3.
Indicators pointing to an interesting week.
Below the moving averages and trending upward. Good for longs, and maybe some short-term gains. Keeping on watch, for sure.
Is today the day?
CHUGGA-CHUGGA---CHOOOOOOOOOOOO CHOOOOOOOOOOO
I think I can... I think I can...
I guess they need to fill the gap at $1.20
Piece of garbage
Followers
|
64
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1727
|
Created
|
08/15/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |